A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan

Trial Profile

A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 Jan 2018 Status changed from completed to discontinued, according to results published in the Journal of Clinical Hypertension (Greenwich).
    • 16 Jan 2018 Results published in the Journal of Clinical Hypertension (Greenwich)
    • 14 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top